UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | J | K | L | M | N | O | P | S | T | W
Number of items: 134.

A

Al-Azraqi, A and Angus, B and Gokul, S and Sinha, D and Calvert, AH and Lunec, J (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. British Journal of Cancer , 80 178 - ?.

Al-Azraqi, A and Angus, B and Gokul, S and Sinha, D and Calvert, AH and Lunec, J (1999) Bcl-2 expression is a potential prognostic co-factor with P53-mutation status in epithelial ovarian carcinoma. BRIT J CANCER , 80 73 - 73.

Al-Mufti, RAM and Pedley, RB and Marshall, D and Begent, RHJ and Hilson, A and Winslet, MC and Hobbs, KEF (1999) In vitro assessment of Lipiodol-targeted radiotherapy for liver and colorectal cancer cell lines. BRIT J CANCER , 79 (11-12) 1665 - 1671.

Al-Mufti, RAM and Pedley, RB and Marshall, D and Begent, RHJ and Winslet, MCAH and K, EF (1999) In vitro assessment of lipiodol targeted radiotherapy for primary and metastatic liver cancers. British Journal of Cancer , 79 1665 - 1671.

Arris, CE and Boyle, FT and Calvert, AH and Curtin, NJ and Dewsbury, PJ and Endicott, JA and Gibson, AE and Golding, BT and Grant, S and Griffin, RJ and Johnson, LN and Noble, MEM and Newell, DR and Sausville, E and Schultz, R (1999) In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors. British Journal of Cancer , 80 110 - ?.

B

Batey, MA and Wright, JG and Simmonds, D and Proctor, M and Chapman, F and Fishwick, K and Azzabi, A and Newell, DR and Lind, MJ and Calvert, AH and Boddy, AV (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. British Journal of Cancer , 80 259 - ?.

Batey, MA and Wright, JG and Simmonds, D and Proctor, M and Chapman, F and Fishwick, K and Azzabi, A and Newell, DR and Lind, MJ and Calvert, AH and Boddy, AV (1999) Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer. BRIT J CANCER , 80 93 - 93.

Begent, RHJ (1999) Targeting cancer therapy. In: BRITISH JOURNAL OF CANCER. (pp. 104 - 109). CHURCHILL LIVINGSTONE

Bentzen, SM and Saunders, MI and Dische, S (1999) Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiotherapy and Oncology , 53 219 - 226.

Boxer, G and Stuart-Smith, S and Flynn, A and Green, A and Begent, R (1999) Radioimmunoluminography: a tool for relating tissue antigen concentration to clinical outcome. BRITISH JOURNAL OF CANCER , 80 (5-6) 922 - 926. 10.1038/sj.bjc.6690443.

Bramwell, VHC and Steward, WP and Nooij, M and Whelan, J and Craft, AW and Grimer, RJ and Taminau, AHM and Cannon, SR and Malcolm, AJ and Hogendoorn, PCW and Uscinska, B and Kirkpatrick, AL and Machin, D and Van Glabbeke, MM (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study. J CLIN ONCOL , 17 (10) 3260 - 3269.

Bramwell, VHC and Steward, WP and Nooij, M and Whelan, J and Craft, AW and Grimer, RJ and Taminau, AHM and Cannon, SR and Malcolm, AJ and Hogendoorn, PCW and Uscinska, B and Kirkpatrick, AL and Machin, D and VanGlabbeke, MM (1999) Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: A European osteosarcoma intergroup study. Journal Of Clinical Oncology , 17 3260 - 3269.

Bridgewater, JA and Nelstrop, AE and Rustin, GJ and Gore, ME and McGuire, WP and Hoskins, WJ (1999) Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel. J Clin Oncol , 17 (2) 501 - 508.

Brooks, N and Mchugh, PJ and Lee, M and Hartley, JA (1999) Repair of DNA damage produced by sequence specific minor groove alkylating agent. PROC AM ASSOC CANCER RES , 40 4118 - 4118.

Brooks, N and McHugh, PJ and Lee, M and Hartley, JA (1999) The role of base excision repair in the repair of DNA adducts formed by a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size. ANTI-CANCER DRUG DES , 14 (1) 11 - 18.

Burcombe, RJ and Ostler, PJ and Ayoub, AW and Hoskin, PJ (1999) Staging CT scans in prostate cancer treatment: A retrospective audit. British Journal of Cancer , 80 157 - 157.

C

Calabrese, CR and Thomas, HD and Batey, MA and Boritzki, T and Zhang, K and White, AW and Curtin, NJ and Griffin, RJ and Golding, BT and Hostomsky, Z and Calvert, AH and Newell, DR (1999) Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase. Clinical Cancer Research , 5 543 - ?.

Calvert, AH and Ghokul, S and Al-Azraqi, A and Wright, J and Lind, M and Bailey, N and Highley, M and Siddiqui, N and Lunec, J and Sinha, D and Boddy, A and Roberts, F and Fenwick, J (1999) Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene. SEMINARS IN ONCOLOGY , 26 (1) 90 - 94.

Calvert, AH and Hughes, AN and Calvert, PM and Plummer, RE and Highley, MS (1999) MTA (LY231514) demonstrates clinical activity against malignant mesothelioma in a phase I combination trial with carboplatin. European Journal of Cancer , 35 1146 - ?.

Calvert, AH and Sessa, C and Hughes, A and Jochim, U and Calvert, P and Ghielmini, M and Renard, J and Gupta, E and Sonnichsen, D and Gallant, G (1999) Pharmacokinetics (PK) of BMS-184476, a new taxane analog, given weekly in patients with advanced malignancies. European Journal of Cancer , 35 1147 - ?.

Calvert, H (1999) An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. SEMINARS IN ONCOLOGY , 26 (2) 3 - 10.

Calvert, H (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, H (1999) MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions. Semin Oncol , 26 (2 Suppl 6) 105 - 108.

Calvert, H (1999) MTA: Summary and conclusions. SEMIN ONCOL , 26 (2) 105 - 108.

Calvert, PM and Highley, MS and Hughes, AN and Plummer, ER and Azzabi, AST and Verrill, MW and Camboni, MG and Verdi, E and Bernareggi, A and Zucchetti, M and Robinson, AM and Carmichael, J and Calvert, AH (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. Clinical Cancer Research , 5 333 - ?.

Calvert, PM and Highley, MS and Hughes, AN and Plummer, ER and Azzabi, AST and Verrill, MW and Camboni, MG and Verdi, E and Bernareggi, A and Zucchetti, M and Robinson, AM and Carmichael, J and Calvert, AH (1999) A phase I study of a novel, trinuclear, platinum analogue, BBR3464, in patients with advanced solid tumors. CLIN CANCER RES , 5 3796S - 3796S.

Casey, JL and Pedley, RB and King, DJ and Boden, R and Chapman, AP and Yarranton, GT and Begent, RHJ (1999) Improved tumour targeting of di-Fab ' fragments modified with polyethylene glycol. TUMOR TARGET , 4 (4) 235 - 244.

Casey, JL and Pedley, RB and King, DJ and Green, AJ and Yarranton, GT and Begent, RH (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. Br J Cancer , 81 (6) 972 - 980. 10.1038/sj.bjc.6690795.

Casey, JL and Pedley, RB and King, DJ and Green, AJ and Yarranton, GT and Begent, RHJ (1999) Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments. BRIT J CANCER , 81 (6) 972 - 980.

Cassoni, AM and Whelan, JS (1999) Ewing's sarcoma: hyperfractionated radiotherapy with concurrent chemotherapy: acute toxicity. A prospective single institutional study. In: Sarcoma. (pp. 45 - 45).

Chang, J and Powles, TJ and Allred, DC and Ashey, SE and Clark, GM and Makris, A and Assersohn, L and Gregory, RK and Osborne, CK and Dowsett, M (1999) Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. Journal Of Clinical Oncology , 17 3058 - 3063.

Chester, KA and Melton, RG and Hawkins, RR (1999) Phage technology for producing antibody enzyme fusion proteins. In: Melton, RG and Fox, RJ, (eds.) Enzyme-Prodrug Strategies for Cancer Therapy. Klewer Academic/Plenum Press

Cooke, SP and Pedley, RB and Boden, R and Holliger, P and Winter, G and Begent, RHJ and Chester, KA (1999) Tumour targeting using MFE-23 :: TNF alpha fusion protein. BRIT J CANCER , 80 85 - 85.

Cooke, SP and Pedley, RB and Boden, R and Holliger, P and Winter, G and Begent, RHJ and Chester, KA (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. British Journal of Cancer , 80 228 - 228.

Cooke, SP and Pedley, RBB and R, H and P, W and G, B and R H J and Chester, KA (1999) Tumour targeting using MFE::TNF fusion protein. In: (Proceedings) Proceedings BACR, Br J Cancer. (pp. 85 - ?).

Cooooke, SP and Pedley, RB and Boden, R and Holliger, P and Winter, G and Begent, RHJ and Chester, KA (1999) Tumour targeting using MFE-23::TNF alpha fusion protein. In: (Proceedings) British Journal of Cancer. (pp. 228 - 228).

Cummins, D and Hoskin, P and Young, J and Goodman, IL and Coupe, MO and Halil, O and Foy, CJ (1999) Is a man's facial appearance predictive of how he will die? International Journal of Clinical Practice , 53 140 - 141.

Curtin, NJ and Bowman, KJ and Turner, RN and Huang, B and Loughlin, PJ and Calvert, AH and Golding, BT and Griffin, RJ and Newell, DR (1999) Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha(1)-acid glycoprotein binding. BRIT J CANCER , 80 (11) 1738 - 1746.

Curtin, NJ and Kyle, S and Wang, LZ and Durkacz, BW and White, AJ and Srinivasan, S and Griffin, RJ and Golding, BTG and Newell, DR and Calvert, AH and Maegley, K and Hostomsky, Z (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. Clinical Cancer Research , 5 520 - ?.

Curtin, NJ and Kyle, S and Wang, LZ and Durkacz, BW and White, AJ and Srinivasan, S and Griffin, RJ and Golding, BTG and Newell, DR and Calvert, AH and Maegley, K and Hostomsky, Z (1999) Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors. CLIN CANCER RES , 5 3834S - 3834S.

D

De Silva, IU and Clingen, PH and McHugh, PJ and Tilby, MJ and Gregson, SJ and Howard, P and Thurston, DE and Hartley, JA (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. BRIT J CANCER , 80 42 - 42.

Deighton, A and Winfield, EA and Venables, K and Aird, EGA and Hoskin, PJ (1999) Variation in dose distribution for breast radiotherapy: A trial based quality assurance programme in the UK. European Journal of Cancer , 35 342 - 342.

Delaney, CA and Wang, LZ and Kyle, LZ and Srinivasan, S and White, AW and Curtin, NJ and Calvert, AH and Durkacz, BW and Newell, DR (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. British Journal of Cancer , 80 62 - ?.

Delaney, CA and Wang, LZ and Kyle, LZ and Srinivasan, S and White, AW and Curtin, NJ and Calvert, AH and Durkacz, BW and Newell, DR (1999) Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines. BRIT J CANCER , 80 44 - 44.

DeSilva, IU and Clingen, PH and Mchugh, PJ and Tilby, MJ and Gregson, SJ and Howard, P and Thurston, DE and Hartley, JA (1999) The role of nucleotide excision repair in the repair of DNA damage induced by mono- and bifunctional, major and minor groove alkylating agents. British Journal of Cancer , 80 55 - 55.

Dische, S and Saunders, MI (1999) The CHART regimen and morbidity [Full text available, price (Pounds)16.45]. Acta Oncologica , 38 147 - 152.

Dische, S and Saunders, MI and Sealy, R and Werner, ID and Verma, N and Foy, C and Bentzen, SM (1999) Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiotherapy and Oncology , 53 93 - 98.

Dowsett, M and Smith, IE and Powles, TJ and Salter, J and Ellis, PM and Johnston, SRD and Makris, A and Mainwaring, P and Gregory, RK and Archer, C and Chang, J and Assersohn, L (1999) Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience. In: Howell, A and Dowsett, M, (eds.) ESO Scientific Updates. (113 - 125). Elsevier Science

F

Flynn, AA and Green, AJ and Boxer, G and Pedley, RB and Begent, RH (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. Phys Med Biol , 44 (7) N151 - N159.

Flynn, AA and Green, AJ and Boxer, G and Pedley, RB and Begent, RHJ (1999) A comparison of image registration techniques for the correlation of radiolabelled antibody distribution with tumour morphology. PHYS MED BIOL , 44 (7) N151 - N159.

Flynn, AA and Green, AJ and Boxer, GM and Casey, JL and Pedley, RB and Begent, RHJ (1999) A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model. INT J RADIAT ONCOL , 43 (1) 183 - 189.

Frohlich, B and Paulussen, M and Craft, A and Judson, I and Ladenstein, R and Oberlin, O and Whelan, JS and Zoubek, A and Jurgens, HFEICESS92UE-E99 (1999) Therapiekonzepte bei non-responden/rezidivpatienten mit Eing Sarkomen im kindesalter. In: Annual Meeting of German and Austrian Socities of Haematology and Oncology, October 3-6th 1999. Onkologie Supp II vol 22.

G

Gander, M and Hartley, JM and Spanswick, VJ and Webley, SD and Hochhauser, D and Hartley, JA (1999) Measurment of DNA interstrand crosslinking in clinical samples using the single cell gel electrophoresis. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH , 40 3410 - 3410.

Ghazal-Aswad, S and Tilby, MJ and Lind, M and Baily, N and Sinha, DP and Calvert, AH and Newell, DR (1999) Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels. ANN ONCOL , 10 (3) 329 - 334.

GlynneJones, R and Saunders, MI and Hoskin, P and Phillips, H (1999) A pilot study of continuous, hyperfractionated, accelerated radiotherapy in rectal adenocarcinoma. Clinical Oncology , 11 334 - 339.

Goodchild, K and Hoskin, P and Dische, S and Pigott, K and Powell, M and Saunders, M (1999) A feasibility study of continuous hyperfractionated accelerated radiotherapy (CHART) and brachytherapy in patients with early oral or oropharyngeal carcinomas. Radiotherapy and Oncology , 50 29 - 31.

Goodchild, KA and Hill, SA and Hoskin, PJ and Saunders, MI and Chaplin, DJ (1999) Low dose nicotinamide and carbogen improve human tumour blood flow. British Journal of Cancer , 80 244 - 244.

Gorodetsky, R and Lotan, C and Piggot, K and Pierce, LJ and Polyansky, I and Dische, S and Saunders, MI and Lichter, AS and Vexler, A (1999) Late effects of dose fractionation on the mechanical properties of breast skin following post-lumpectomy radiotherapy. International Journal of Radiation Oncology Biology Physics , 45 893 - 900.

Green, AJ and Adamson, KL and Begent, RH (1999) Validation of a gamma camera PET system for serial 18F-FDG imaging for the measurement of response to anti-cancer therapies. Journal of Nuclear Medicine , 40 1246 - 1246.

Griffin, RJ and Barlow, HC and Curtin, NJ and Calvert, AH and Golding, BT and Newell, DR and Smith, PG (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). Clinical Cancer Research , 5 564 - ?.

Griffin, RJ and Barlow, HC and Curtin, NJ and Calvert, AH and Golding, BT and Newell, DR and Smith, PG (1999) 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP). CLIN CANCER RES , 5 3843S - 3843S.

Grimaldi, KA and Bingham, JP and Hartley, JA (1999) PCR-based assays for strand-specific measurement of DNA damage and repair. I. Strand-specific quantitative PCR. Methods Mol Biol , 113 227 - 240. 10.1385/1-59259-675-4:227.

Grimaldi, KA and Bingham, JP and Hartley, JA (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair I. In: Henderson, DS, (ed.) Methods in Molecular Biology. (227 - 241). Humana Press Inc

Grimaldi, KA and Mac Adam, SR and Hartley, JA (1999) PCR-Based Assys for Strand-Specific Measurement of DNA Damage and Repair II. In: Henderson, DS, (ed.) Methods in Molecular Biology. (241 - 255). Humana Press

Grimaldi, KA and McAdam, SR and Hartley, JA (1999) PCR-based assays for strand-specific measurement of DNA damage and repair. II. Single-strand ligation-PCR. Methods Mol Biol , 113 241 - 255. 10.1385/1-59259-675-4:241.

H

Hargreaves, RHJ and O'Hare, CC and Hartley, JA and Ross, D and Butler, J (1999) Cross-linking and sequence-specific alkylation of DNA by aziridinylquinones. 3. Effects of alkyl substituents. J MED CHEM , 42 (12) 2245 - 2250.

Hartley, JA and O'Hare, CC and Baumgart, J (1999) DNA alkylation and interstrand cross-linking by treosulfan. BRIT J CANCER , 79 (2) 264 - 266.

Hartley, JM and Spanswick, VJ and Gander, M and Giacomini, G and Whelan, J and Souhami, RL and Hartley, JA (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. CLIN CANCER RES , 5 (3) 507 - 512.

Hochhauser, D (1999) Cancer researchers get down to arrays at AACR. LANCET , 353 (9162) 1418 - 1418.

Hochhauser, D and Valkov, NI and Gump, JL and Wei, I and O'Hare, C and Hartley, J and Fan, JG and Bertino, JR and Banerjee, D and Sullivan, DM (1999) Effects of wild-type p53 expression on the quantity and activity of topoisomerase II alpha and beta in various human cancer cell lines. J CELL BIOCHEM , 75 (2) 245 - 257.

Hoskin, PJ and Abdelath, O and Phillips, H and Gilligan, S and Saunders, MI and Broderick, P and Baddeley, H (1999) Inspired and expired gas concentrations in man during carbogen breathing. Radiotherapy and Oncology , 51 175 - 177.

Hoskin, PJ and Saunders, MI and Abdellati, O and Broderick, P (1999) Capnometry and blood gas measurements in man during carbogen breathing. British Journal of Cancer , 80 328 - 328.

Hoskin, PJ and Saunders, MI and Dische, S (1999) Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma - Hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide. Cancer , 86 1322 - 1328.

Hoskin, PJ and Saunders, MI and Goodchild, K and Powell, MEB and Taylor, NJ and Baddeley, H (1999) Dynamic contrast enhanced magnetic resonance scanning as a predictor of response to accelerated radiotherapy for advanced head and neck cancer. British Journal of Radiology , 72 1093 - 1098.

Hoskin, PJ and Stratford, M and Folkes, L and Phillips, H and Jackson, S and Regan, J and Yarnold, JR (1999) Bone markers in response to local radiotherapy for bone pain. British Journal of Cancer , 80 28 - 28.

Hughes, A and Calvert, H (1999) An update on thymidylate synthase inhibitors. ANN ONCOL , 10 (10) 1137 - 1139.

Hughes, AN and Rafi, I and Griffin, MJ and Calvert, AH and Newell, DR and Calvete, JA and Johnston, A and Clendeninn, N and Boddy, AV (1999) Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days. CLIN CANCER RES , 5 (1) 111 - 118.

Hunalov, A and Robson, L and Perkins, SJ and Begent, RHJ and Chester, KA (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. British Journal of Cancer , 80 92 - 92.

Hunalov, A and Robson, L and Perkins, SJ and Begent, RHJ and Chester, KA (1999) A vector for expression of dimeric and chelating forms of anti-CEA scFvS. BRIT J CANCER , 80 51 - 51.

J

Joiner, MC and Marples, B and Lambin, P and Short, S and Turesson, I (1999) Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics , 49 (2) 379 - 389.

K

Kiani-Alikhan, S and Chester, KA and Ledermann, JA and Beverley, PCL (1999) Potentiation of the activity of dendritic cells by DNA. In: British Journal of Cancer. (pp. 93 - 93).

Kiani-Alikhan, S and Chester, KA and Ledermann, JA and Beverley, PCL (1999) Potentiation of the activity of dendritic cells by DNA. BRIT J CANCER , 80 52 - 52.

Koberle, B and Masters, JRW and Hartley, JA and Wood, RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. CURR BIOL , 9 (5) 273 - 276.

L

Lee, SM and Radford, JA and Ryder, WD and Deakin, DP and Morgenstern, OR and Scarffe, JH and Crowther, D (1999) Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma. Bone Marrow Transplantation , 24 (3) 271 - 277.

M

Maini, MK and Casorati, G and Dellabona, P and Wack, A and Beverley, PCL (1999) T-cell clonality in immune responses. IMMUNOL TODAY , 20 (6) 262 - 266.

Maini, MK and Soares, MVD and Zilch, CF and Akbar, AN and Beverley, PCL (1999) Virus-induced CD8(+) T cell clonal expansion is associated with telomerase up-regulation and telomere length preservation: A mechanism for rescue from replicative senescence. J IMMUNOL , 162 (8) 4521 - 4526.

Makris, A and Powles, TJ and Allred, DC and Ashley, SE and Trott, PA and Ormerod, MG and Titley, JC and Dowsett, M (1999) Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: A pilot study. Breast Cancer Research And Treatment , 53 51 - 59.

Makris, A and Powles, TJ and Kakolyris, S and Dowsett, M and Ashley, SE and Harris, AL (1999) Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer , 85 1996 - 2000.

Mayer, A and Chester, KA and Flynn, AA and Begent, RH (1999) Taking engineered anti-CEA antibodies to the clinic. J Immunol Methods , 231 (1-2) 261 - 273.

Mayer, A and Chester, KA and Flynn, AA and Begent, RHJ (1999) Taking engineered anti-CEA antibodies to the clinic. J IMMUNOL METHODS , 231 (1-2) 261 - 273.

McHugh, PJ and Gill, RD and Waters, R and Hartley, JA (1999) Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. NUCLEIC ACIDS RES , 27 (16) 3259 - 3266.
An open access publication

Mchugh, PJ and Hartley, JA (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. British Journal of Cancer , 80 54 - 54.

McHugh, PJ and Hartley, JA (1999) The induction and repair of DNA doublestrand breaks in nitrogen mustard treated Saccharomyces cerevisiae cells. BRIT J CANCER , 80 42 - 42.

N

Napier, MP and Hoare, D and Whelan, JS (1999) Safe administration of high dose methotrexate in osteosarcoma: Carboxypeptidase G2 for idiosynchratic toxicity. British Journal of Cancer , 80 155 - 155.

Napier, NP and Hoare, D and Whelan, JS (1999) Safe administration of high dose methotrexate in osteosarcoma: carboxypeptidase G2 for idiosyncratic toxicity. In: British Cancer Research Meeting 1999, Edinburgh.

Neidle, S and Mann, J and Rayner, EL and Baron, A and Opoku-Boahen, Y and Simpson, IJ and Smith, NJ and Fox, KR and Hartley, JA and Kelland, LR (1999) Symmetric bis-benzimidazoles: new sequence-selective DNA-binding molecules. CHEM COMMUN (10) 929 - 930.

Newby, JC and Leonard, P and Fenwick, E and Harland, SJ (1999) A phase II study of epirubicin, carboplatin and infusional 5-FU in hormone resistant prostate cancer. British Journal of Cancer , 80 158 - 158.

Newell, DR and Arris, CE and Boyle, FT and Calvert, AH and Curtin, NJ and Dewsbury, P and Endicott, JA and Garman, EF and Gibson, AE and Golding, BT and Griffin, RJ and Johnson, LN and Lawrie, A and Noble, MEM and Sausville, EA and Schultz, R (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. Clinical Cancer Research , 5 124 - ?.

Newell, DR and Arris, CE and Boyle, FT and Calvert, AH and Curtin, NJ and Dewsbury, P and Endicott, JA and Garman, EF and Gibson, AE and Golding, BT and Griffin, RJ and Johnson, LN and Lawrie, A and Noble, MEM and Sausville, EA and Schultz, R (1999) Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. CLIN CANCER RES , 5 3755S - 3755S.

Nutting, C and Brada, M and Brazil, L and Sibtain, A and Saran, F and Westbury, C and Moore, A and Thomas, DG and Traish, D and Ashley, S (1999) Radiotherapy in the treatment of benign meningioma of the skull base. J Neurosurg , 90 (5) 823 - 827. 10.3171/jns.1999.90.5.0823.

O

Osborne, M and GlynneJones, R and Galbraith, S and Burcombe, R and Makris, A (1999) Squamous cell carcinoma antigen as a marker of epidermoid carcinoma of the anal canal. British Journal of Cancer , 80 117 - 117.

Osborne, M and GlynneJones, R and Hoskin, P and Saunders, M and Makris, A (1999) Continuous hyperfractionated accelerated radiotherapy +/-concurrent infusional 5FU in advanced rectal cancer. British Journal of Cancer , 80 114 - 114.

Osbourn, JK and McCafferty, J and Derbyshire, EJ and Waibel, R and Chester, K and Boxer, G and Allen, D (1999) Isolation of a panel of human anti-CEA single chain Fv from a large phage display library. Tumor Targeting , 4 150 - 157.

P

Paniwnyk, Z and Pors, K and TeesdaleSpittle, PH and Potter, GA and Plumb, J and Hartley, JA and Patterson, LH (1999) Novel inhibitor of topo II is effective against resistant ovarian cancer cells. British Journal of Cancer , 80 69 - 69.

Parkinsoin, MC and Harland, SJ (1999) Testis cancer. In: Mundy, AR and Fitzpatrick, JM and Neal, DE and George, NJR, (eds.) Scientific Basis of Urology. (375 - 394). Isis Medical Media Ltd: Oxford, UK.

Pedley, RB and Sharma, SK and Boxer, GM and Boden, R and Stribbling, SM and Davies, L and Springer, CJ and Begent, RH (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res , 59 (16) 3998 - 4003.

Pedley, RB and Sharma, SK and Boxer, GM and Boden, R and Stribbling, SM and Davies, L and Springer, CJ and Begent, RHJ (1999) Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. CANCER RES , 59 (16) 3998 - 4003.

Plummer, R and Rees, C and Judson, I and Calvert, H and Highley, M and Trigo, J and Jackman, A and Smith, R and Hutchison, M and Smith, M (1999) Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks. EUR J CANCER , 35 S285 - S285.

Powell, MEB and Collingridge, DR and Saunders, MI and Hoskin, PJ and Hill, SA and Chaplin, DJ (1999) Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiotherapy and Oncology , 50 167 - 171.

S

Saunders, MI and Dische, S and Barrett, A and Harvey, A and Griffiths, G and Parmar, MKB (1999) Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer; Mature data from the Randomised Multicentre Trial. Radiotherapy and Oncology , 52 137 - 148.

Saunders, MI and Dische, S and Rojas, A (1999) CHART (continuous, hyperfractionated, accelerated radiotherapy): a tale of two disciplines. British Journal of Cancer , 80 110 - 115.

Shamash, J and Lee, SM and Deakin, DP and Scarffe, JH and Morgenstern, GR and Chang, J and Gupta, RK and Rohatiner, AZS and Radford, JA and Lister, TA (1999) High dose chemotherapy (HDCT) with autologous haematopoietic support in recurrent or refractory Hodgkin’s lymphoma (HL). In: (Proceedings) British Cancer Research Meeting, Edinburgh.. (pp. 18 - ?). British Journal of Cancer

Shanker, A and Renaut, AJ and Whelan, JS and Taylor, I (1999) Colorectal cancer in adolescents. Annals of the Royal College of Surgeons of England , 81 (2) 100 - 104.

Short, S (1999) UNSPECIFIED In: (Proceedings) The Royal College of Radiologists Annual Scientific Meeting.

Short, S (1999) The response of human glioma cells to low dose radiation. International journal of radiation biology , 75 1341 - 1348.

Short, S and Mayes, C and Woodcock, M and Joiner, MC (1999) Low-dose hypersensitivity in the T98G glioblastoma cell line. International journal of radiation biology , 75 847 - 855.

Sirotnak, FM and Tolner, B (1999) Carrier-mediated membrane transport of folates in mammalian cells. ANNU REV NUTR , 19 91 - 122.

Smith, PG and Barlow, HC and Loughlin, P and Huang, B and Bowman, KJ and Calvert, AH and Curtin, NJ and Golding, BT and Griffin, RJ and Newell, DR (1999) Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein. British Journal of Cancer , 80 82 - ?.

Smith, PG and Bewley, J and Gogel, JA and Calvert, AH and Newell, DR and Curtin, NJ and Chen, VJ (1999) MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines. British Journal of Cancer , 80 83 - ?.

Smith, PG and Marshman, E and Calvert, AH and Newell, DR and Curtin, NJ (1999) Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines. SEMINARS IN ONCOLOGY , 26 (2) 63 - 67.

Spanswick, VJ and Hartley, JM and Ward, TH and Hartley, JA (1999) Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay. Methods Mol Med , 28 143 - 154. 10.1385/1-59259-687-8:143.

Spencer, DIR and Robson, L and Bhatia, J and Sharma, SK and Michael, NP and Whitelegg, NR and Rees, AR and Chester, KA and Begent, RHJ (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. In: BRITISH JOURNAL OF CANCER. (pp. 94 - 94).

Spencer, DIR and Robson, L and Bhatia, J and Sharma, SK and Michael, NP and Whitelegg, NR and Rees, AR and Chester, KA and Bergent, RHJ (1999) Identifying immunogenic sites on adept enzymes CPG2 using a SCFV phage library & SELDI (TM)-AMS. BRIT J CANCER , 80 52 - 52.

Strauss, S and McTiernan, A and Whelan, JS (1999) Recurrence of osteosarcoma after disease-free intervals exceeding 5 years. In: British Orthopaedic Oncology Society, March 1999.

Summers, Y and Middleton, MR and Calvert, H and Lee, SM and Rustin, R and Newell, DR and Thatcher, N (1999) Effect of temozolomide (TMZ) on central nervous system relapse in patients with advanced melanoma. In: (Proceedings) 1999 ASCO Annual Meeting/35th Annual Meeting, Atlanta, GA.. (pp. 531a - ?). Proceedings of the American Society of Clinical Oncology

T

Tolner, B and Singh, A and Esaki, T and Roy, K and Sirotnak, FM (1999) Transcription of the mouse RFC-1 gene encoding a folate transporter. Multiplicity and properties of promoters with minimum requirements for their basal activity. GENE , 231 (1-2) 163 - 172.

W

Webley, SD and Francis, R and Begent, RHJ and Hartley, JA and Hochhauser, D (1999) Measurement of the critical DNA lesions produced by antibody directed enzyme prodrug therapy (ADEPT). BRIT J CANCER , 80 47 - 47.

Wedderburn, LR and Maini, MK and Patel, A and Beverley, PCL and Woo, P (1999) Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood. INT IMMUNOL , 11 (4) 535 - 543.

Whelan, J and Hoare, D and Leonard, P (1999) Omeprazole does not alter plasma methotrexate clearance. Cancer Chemotherapy and Pharmacology , 44 (1) 88 - 89.

Whelan, JS and Goodchild, K and Strauss, S and McTiernan, A and Driver, D and Kilby, AM and Cassoni, AM (1999) Intensive induction therapy (VIDE) including stem cell collection for Ewing's family of tumours. In: British Cancer Research Meeting 1999, Edinburgh.

Wilson, SC and Howard, PW and Forrow, SM and Hartley, JA and Adams, LJ and Jenkins, TC and Kelland, LR and Thurston, DE (1999) Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2,1-c][1,4]benzodiazepine system. J MED CHEM , 42 (20) 4028 - 4041.

Woll, P and Judson, I and Lee, SM and Rodenhuis, S and Nielsen, OS and Buesa, JM and Lorigan, PC and Leyvraz, S and Hermans, C and van, GM and Verweij, J (1999) Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma group. European Journal of Cancer , 35 (3) 410 - 412.

Woll, PJ and Carmichael, J and Chan, S and Howell, A and Ranson, M and Miles, D and Calvert, H and Welbank, H (1999) Phase II study results on safety and efficacy of CAELYX (R) (DOXIL (R)) in combination with paclitaxel in the treatment of metastatic breast cancer. EUR J CANCER , 35 S322 - S322.

Wong, KCK and Meyer, T and Harding, DI and Dick, JRT and Vrbova, G and Greensmith, L (1999) Integrins at the neuromuscular junction are important for motoneuron survival. EUR J NEUROSCI , 11 (9) 3287 - 3292.

This list was generated on Fri May 24 09:59:20 2013 BST.